Article Details

AstraZeneca cancer drug Enhertu added for reimbursement in China despite probe

Retrieved on: 2024-11-28 17:59:34

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca cancer drug Enhertu added for reimbursement in China despite probe. View article details on hiswai:

Excerpt

AstraZeneca's (NASDAQ:AZN) blockbuster cancer medication, Enhertu, developed with Japanese pharma giant Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) ...

Article found on: seekingalpha.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up